Browsing Tag
iTolerance Inc.
1 post
NLS Pharmaceutics and Kadimastem merger gains BIRD Foundation boost for breakthrough Type 1 diabetes therapy
Discover how NLS Pharmaceutics and Kadimastem’s merger, backed by renewed BIRD Foundation funding, positions NewCelX to challenge global leaders in diabetes cell therapy.